GERMANTOWN, Md., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NYSE:SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced that it plans to release its third quarter 2024 financial results after market close on Thursday, November 7, 2024. Management will hold a conference call to review the Company's third quarter 2024 performance starting at 4:30 p.m. (Eastern Time) on the same day. The conference call will be concurrently webcast. The link to the webcast will be available on Senseonics Holdings, Inc. website at www.senseonics.com by nav

Senseonics Holdings, Inc. (NYSE:SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today reported financial results for the second quarter ended June 30, 2024. Recent Highlights & Accomplishments: Generated revenue of $4.9 million in the second quarter of 2024, representing growth of more than 18% compared to the prior year period FDA review of the 510(k) submission for the next-generation 365-day Eversense® system and operational readiness activities continue to advance for planned fourth quarter 2024 product launch Continued to advance the collaboration

Senseonics Holdings, Inc. (NYSE:SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced that it plans to release its second quarter 2024 financial results after market close on Thursday, August 8, 2024. Management will hold a conference call to review the Company's second quarter 2024 performance starting at 4:30 p.m. (Eastern Time) on the same day. The conference call will be concurrently webcast. The link to the webcast will be available on Senseonics Holdings, Inc. website at www.senseonics.com by navigating to "Investor Relations," and then "Events &

Senseonics Holdings, Inc. (NYSE:SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today reported financial results for the quarter ended March 31, 2024. Recent Highlights & Accomplishments: Generated revenue of $5.1 million in the first quarter of 2024, representing growth of 22% compared to the prior year period Announced integration of Eversense® CGM and the Eversense Remote Patient Monitoring (RPM) solution within St. Louis-based Mercy health care system, a major healthcare provider serving three million patients annually, including 30,000 potential CGM u

Senseonics Holdings, Inc. (NYSE:SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced that it plans to release its first quarter 2024 financial results after market close on Monday, May 13, 2024. Management will hold a conference call to review the Company's first quarter 2024 performance starting at 4:30 p.m. (Eastern Time) on the same day. The conference call will be concurrently webcast. The link to the webcast will be available on Senseonics Holdings, Inc. website at www.senseonics.com by navigating to "Investor Relations," and then "Events & Publi

Senseonics Holdings, Inc. (NYSE:SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today reported financial results for the quarter and full year ended December 31, 2023. Recent Highlights & Accomplishments: Generated revenue of $8.0 million in the fourth quarter of 2023, representing growth of 44% compared to the prior year period and revenue of $22.4 million in the full year 2023, representing growth of 37% compared to 2022 Brian Hansen appointed President of CGM at Ascensia Diabetes Care, leading the newly created independent business unit and its dedicate

Senseonics Holdings, Inc. (NYSE:SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced that it plans to release its fourth quarter and full year 2023 financial results after market close on Thursday, February 29, 2024. Management will hold a conference call to review the Company's fourth quarter and full year 2023 performance starting at 4:30 p.m. (Eastern Time) on the same day. The conference call will be concurrently webcast. The link to the webcast will be available on Senseonics Holdings, Inc. website at www.senseonics.com by navigating to "Investor

Newly Created Leadership Role Reinforces PHC Group Commitment to Diabetes Innovation PHC Holdings Corporation (TSE: 6523) (hereafter PHCHD), the parent company of Ascensia Diabetes Care, a global diabetes care company, along with Senseonics Holdings, Inc. (NYSE:SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced that diabetes industry veteran Brian Hansen has been appointed to the newly created role of President of CGM at Ascensia Diabetes Care, effective February 6, 2024. Ascensia is the exclusive global distributor of the Eversense® E3 CGM system d

Senseonics Holdings, Inc. (NYSE:SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today reported financial results for the quarter ended September 30, 2023. Recent Highlights & Accomplishments: Generated revenue of $6.1 million in the third quarter of 2023 Announced the last patient completion of the 365-day ENHANCE Pivotal Clinical Study adult cohort Launched with our global commercial partner Ascensia Diabetes Care, a new direct to consumer U.S. advertising campaign, ‘The CGM for Real Life' to increase awareness of Eversense's unique benefits Entered

Senseonics Holdings, Inc. (NYSE-American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced that it plans to release its third quarter 2023 financial results after market close on Thursday, November 9, 2023. Management will hold a conference call to review the Company's third quarter 2023 performance starting at 4:30 p.m. (Eastern Time) on the same day. The conference call will be concurrently webcast. The link to the webcast will be available on Senseonics Holdings, Inc. website at www.senseonics.com by navigating to "Investor Relations," and then

GERMANTOWN, Md., Oct. 25, 2024 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NYSE:SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced that it has entered into a definitive agreement for the purchase and sale of 45,714,286 shares of its common stock at an offering price of $0.35 per share of common stock in a registered direct offering. Additionally, in a concurrent private placement, the Company has agreed to issue unregistered warrants to purchase up to 45,714,286 shares of common stock (the "Warrants"). The Warrants will have an exercise price of $

GERMANTOWN, Md., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NYSE:SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced that it plans to release its third quarter 2024 financial results after market close on Thursday, November 7, 2024. Management will hold a conference call to review the Company's third quarter 2024 performance starting at 4:30 p.m. (Eastern Time) on the same day. The conference call will be concurrently webcast. The link to the webcast will be available on Senseonics Holdings, Inc. website at www.senseonics.com by nav

Manage diabetes and not CGM interruptions with the new Eversense 365 CGM system – the only One Year CGM that is designed to help minimize device frustrations Ascensia launches the world's first One Year CGM system in the US, with broad commercial coverage for people with diabetes Pay as little as $199 out of pocket for One Year of continuous glucose monitoringi, with only one payment a year Ascensia Diabetes Care, a global diabetes care company, announces that it is launching the Eversense® 365 continuous glucose monitoring (CGM) system, the world's only One Year CGM, to people with diabetes in the U.S.ii Developed by Senseonics Holdings, Inc. (NYSE:SENS), Eversense 365 is the only CGM t

Eversense 365 cleared in the U.S. as an integrated continuous glucose monitoring (iCGM) system for people with diabetes With a single sensor, the Eversense 365 system provides one year of use, versus 10-14 days with short-term CGM's for minimal life disruption Launch expected early in the fourth quarter of 2024 GERMANTOWN, Md. and PARSIPPANY, N.J., Sept. 17, 2024 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NYSE:SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes and Ascensia Diabetes Care, a global diabetes care company, today announced that the U.S. Food

GERMANTOWN, Md., Sept. 06, 2024 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NYSE:SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced plans to participate in the upcoming H.C. Wainwright 26th Annual Global Investment Conference, being held in New York, NY. Management is scheduled to participate in the H.C. Wainwright 26th Annual Global Investment Conference on Tuesday, September 10, 2024, at 11:30 am ET and will hold one-on-one meetings. Interested parties may access a live and recorded webcast of the presentation on the "Investor Relations" secti

Senseonics Holdings, Inc. (NYSE:SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today reported financial results for the second quarter ended June 30, 2024. Recent Highlights & Accomplishments: Generated revenue of $4.9 million in the second quarter of 2024, representing growth of more than 18% compared to the prior year period FDA review of the 510(k) submission for the next-generation 365-day Eversense® system and operational readiness activities continue to advance for planned fourth quarter 2024 product launch Continued to advance the collaboration

Senseonics Holdings, Inc. (NYSE:SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced that it plans to release its second quarter 2024 financial results after market close on Thursday, August 8, 2024. Management will hold a conference call to review the Company's second quarter 2024 performance starting at 4:30 p.m. (Eastern Time) on the same day. The conference call will be concurrently webcast. The link to the webcast will be available on Senseonics Holdings, Inc. website at www.senseonics.com by navigating to "Investor Relations," and then "Events &

Senseonics Holdings, Inc. (NYSE:SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced business updates and provided its full year 2024 financial outlook. Business Updates Reaffirmed global net revenue for the first half of 2024 is expected to be $10 million, representing growth of approximately 21% compared to the first half of 2023 Generated over 200% more new patient starts in the US in the first half of 2024 compared to the first half of 2023 FDA review of the 510(k) submission for the next-generation 365-day, once a week calibration, Evers

Senseonics Holdings, Inc. (NYSE:SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced plans to host a business update and analyst event during the American Diabetes Association's 84th Scientific Sessions in Orlando, FL. Breakfast and refreshments will be provided beginning at 9:15 am ET on Sunday, June 23, 2024, in advance of a business update presentation from management scheduled to begin, at 10:00 am ET. Interested parties may access a live and recorded webcast of the presentation on the "Investor Relations" section of the company's website at www.s

Senseonics Holdings, Inc. (NYSE:SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced plans to participate in the upcoming Sidoti Small Cap Conference, being held in virtually. Management is scheduled to participate on Wednesday, June 12, 2024, at 1:45 pm ET and will hold one-on-one meetings. Interested parties may access a live and recorded webcast of the presentation on the "Investor Relations" section of the company's website at www.senseonics.com. About Senseonics Senseonics Holdings, Inc. ("Senseonics") is a medical technology company focused

4 - Senseonics Holdings, Inc. (0001616543) (Issuer)

4 - Senseonics Holdings, Inc. (0001616543) (Issuer)

4 - Senseonics Holdings, Inc. (0001616543) (Issuer)

4 - Senseonics Holdings, Inc. (0001616543) (Issuer)

4 - Senseonics Holdings, Inc. (0001616543) (Issuer)

4 - Senseonics Holdings, Inc. (0001616543) (Issuer)

4 - Senseonics Holdings, Inc. (0001616543) (Issuer)

4 - Senseonics Holdings, Inc. (0001616543) (Issuer)

4 - Senseonics Holdings, Inc. (0001616543) (Issuer)

4 - Senseonics Holdings, Inc. (0001616543) (Issuer)

8-K - Senseonics Holdings, Inc. (0001616543) (Filer)

424B5 - Senseonics Holdings, Inc. (0001616543) (Filer)

424B5 - Senseonics Holdings, Inc. (0001616543) (Filer)

10-Q - Senseonics Holdings, Inc. (0001616543) (Filer)

8-K - Senseonics Holdings, Inc. (0001616543) (Filer)

8-K - Senseonics Holdings, Inc. (0001616543) (Filer)

SD - Senseonics Holdings, Inc. (0001616543) (Filer)

8-K - Senseonics Holdings, Inc. (0001616543) (Filer)

10-Q - Senseonics Holdings, Inc. (0001616543) (Filer)

8-K - Senseonics Holdings, Inc. (0001616543) (Filer)

Jefferies initiated coverage of Senseonics with a rating of Underperform and set a new price target of $0.50

HC Wainwright & Co. initiated coverage of Senseonics Holdings with a rating of Buy and set a new price target of $6.00

SVB Leerink downgraded Senseonics Holdings from Outperform to Market Perform and set a new price target of $3.00

SVB Leerink reiterated coverage of Senseonics Holdings with a rating of Outperform and set a new price target of $3.00 from $1.00 previously

Raymond James downgraded Senseonics Holdings from Market Perform to Underperform

Stifel Nicolaus resumed coverage of Senseonics with a rating of Buy and set a new price target of $1.85

BTIG Research downgraded Senseonics from Buy to Neutral

Gainers Anitra (AMEX:AZTR) shares increased by 6.5% to $0.18 during Wednesday's after-market session. The market value of their outstanding shares is at $5.1 million. Oragenics (AMEX:OGEN) shares increased by 4.24% to $2.04. The market value of their outstanding shares is at $9.1 million. PACS Group (NYSE:PACS) shares rose 3.95% to $31.52. The market value of their outstanding shares is at $4.8 billion. MultiPlan (NYSE:MPLN) shares moved upwards by 3.49% to $0.45. The market value of their outstanding shares is at $290.3 million. Nanoviricides (AMEX:NNVC) stock moved upwards by 2.01% to $2.48. The market value of their outstanding shares is at $29.2 million. Calidi Biotherapeutics (AME

The collaboration marks the first time Senseonics' Eversense CGM technology will be used across a health system and the first implementation of Senseonics' new Eversense Remote Patient Monitoring (RPM) solution to drive significant advancement in diabetes management for patients. In a phased approach, Mercy will roll the program out first in its St. Louis-area communities followed by the remaining regions in Mercy's system in Missouri, Kansas, Arkansas and Oklahoma throughout 2025.

Senseonics Holdings (AMEX:SENS) reported quarterly losses of $(0.03) per share which met the analyst consensus estimate. The company reported quarterly sales of $5.047 million which beat the analyst consensus estimate of $4.605 million by 9.60 percent. This is a 22.00 percent increase over sales of $4.137 million the same period last year.

HC Wainwright & Co. analyst Vernon Bernardino reiterates Senseonics Holdings (AMEX:SENS) with a Buy and maintains $2 price target.

s